Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of SAR341402 Mix 70/30 vs NovoLog Mix 70/30 in Type 1 Diabetes
NCT03916601Phase 1Completed
- Sponsor
- Sanofi
- Start
- Dec 2017
- Primary completion
- Mar 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin aspart in type 1 diabetes mellitus (T1D) (4 arms), sponsored by Sanofi. Primary endpoints: Maximum insulin concentration at 24 hours, Area under the insulin concentration time curve and 2 more. Started Dec 2017; status: completed.
02
Drugs
insulin aspart
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03916601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03916601.